Ended the year with strong cash position of $59.2 million Revenues grew 81% year-over-year to $0.5 million for Q4 2021 Revenues grew 72% year-over-year to $1.5 million for FY 2021 Gross profit of $31,818 for Q4 2021 Completed the acquisition of the Neurology Centre of Toronto in September 2021 Two clinical trials about to launch: Phase 1 study for proprietary psilocybe extract and Phase 3 open…


Previous articlePTSF88 – Dr. Ben Sessa of Awakn Life Sciences + Josh Bartch of Mydecine Innovations Group
Next articlePsychedelic Bulletin: Our Dispatch from Horizons NYC; NIDA to Study Delix Compounds